Camostatum

Camostatum Uses, Dosage, Side Effects, Food Interaction and all others data.

Camostatum mesylate, or FOY-305, is a synthetic serine protease inhibitor. It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. Camostatum mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19.

Camostatum mesylate was first approved in Japan in January 2006.

Camostatum mesylate is a protease inhibitor used to treat chronic pancreatitis. The duration of action is not long, as it is typically given in 3 divided doses daily. Patients should be counselled regarding the risk of anaphylaxis, thrombocytopenia, hepatic dysfunction, and hyperkalemia.

Trade Name Camostatum
Generic Camostat
Camostat Other Names Camostat, Camostatum
Type
Formula C20H22N4O5
Weight Average: 398.4125
Monoisotopic: 398.159019834
Protein binding

Camostat mesylate is 25.8-28.2% protein bound to human serum proteins in vitro.

Groups Experimental
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Camostatum
Camostatum

Uses

Camostatum is a serine protease indicated in Japan to treat chronic pancreatitis.

Camostatum mesylate is indicated in Japan to treat chronic pancreatitis and drug induced lung injury. It is also being investigated as a potential treatment for COVID-19.

How Camostatum works

In rats, oral camostat mesylate may increase pancreatic secretions and hypertrophy by increasing cholecystokinin release. Administration in rats has also lead to lower levels of IL-1beta, IL-6, TNF-alpha, TGF-beta, and PSC. Similar activity is seem after administration in humans, leading to reduced pain and inflammation as well as improve the function of the pancrease in chronic pancreatitis.

In the case of SARS-CoV-2, camostat mesylate inhibits the action of the serine protease TMPRSS2, preventing the priming of the viral spike protein for attachment to ACE2, and entry into the cell.

Toxicity

Data regarding overdoses of camostat mesylate are not readily available, however common adverse effects include rash, pruritus, nausea, abnormal laboratory test values, and diarrhea.

Food Interaction

  • Take with food. Take after a meal.

Volume of Distribution

The volume of distribution at steady state of camostat mesylate is 0.34-1.31L/kg.

Elimination Route

A 200mg oral dose of camostat mesylate leads to the active metabolite reaching a Cmax of 87.1 ± 29.5 ng/mL, with a Tmax of 40 min, and an AUC of 10,400 ± 1,400 ng*min/mL.

Half Life

The half life of camostat mesylate is 3.8-4.7h.

Clearance

The clearance of camostat mesylate is 4.5-7.3mL/min/kg.

Elimination Route

Camostatum mesylate is 89.8-95.6% eliminated in the urine and 1.0-1.7% eliminated in the feces.

Innovators Monograph

You find simplified version here Camostatum

*** Taking medicines without doctor's advice can cause long-term problems.
Share